PROBLEM TO BE SOLVED: To provide pharmaceutical combinations for treating or preventing ophthalmologic conditions being age-related macular degeneration, polypoid choroidea angiopathy, conditions related to choroidea angiogenesis, hypertensive retinopathy, diabetic retinopathy, sickle cell retinopathy, conditions related to peripheral retinal angiogenesis, retinopathy of prematurity, veno-occlusive disease, arterial occlusive disease, central serous chorioretinopathy, cystoid macular edema, retinal telangiectasia, microaneurysm, retinal angiomatosis, radiation induced retinopathy, iris rubeosis or neoplasm.SOLUTION: Provided is a combination of a PDGF antagonist and a VEGF antagonist such as Aflibercept, KH902 VEGF receptor-Fc fusion protein, sFLT01, sFLT02, or a pharmaceutically acceptable salt thereof.【課題】加齢性黄斑変性症、ポリープ状脈絡膜血管症、脈絡膜血管新生に関連する病態、高血圧性網膜症、糖尿病性網膜症、鎌状赤血球網膜症、末梢網膜新生血管に関連する病態、未熟児網膜症、静脈閉塞性疾患、動脈閉塞性疾患、中心性漿液性脈絡網膜症、類嚢胞黄斑浮腫、網膜毛細血管拡張症、細動脈瘤、網膜血管腫症、放射線誘発網膜症、虹彩ルベオーシス又は新生物である眼科疾患を処置又は予防するための医薬的組み合わせの提供。【解決手段】ＰＤＧＦアンタゴニスト及びアフリベルセプト、ＫＨ９０２ ＶＥＧＦ受容体－Ｆｃ融合タンパク質、ｓＦＬＴ０１、ｓＦＬＴ０２、又はこれらの医薬的に許容される塩であるＶＥＧＦアンタゴニストとの組み合わせ。【選択図】なし
